Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG

Kurian, Kathreena M.; Jenkinson, Michael D.; Brennan, Paul M.; Grant, Robin; Jefferies, Sarah; Rooney, Alasdair G; Bulbeck, Helen; Erridge, Sara; Mills, Samantha J.; McBain, Catherine; McCabe, Martin G.; Price, Stephen J.; Marino, Silvia; Moyes, Erica; Qian, W.; Waldman, Adam; Vaqas, Babar; Keatley, Debbie; Burchill, Peter; Watts, Colin

doi:10.1093/nop/npx022

Cited by 8 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The United Kingdom is strategically well-placed to contribute to and lead research into survivorship, quality of life and patient-reported outcomes [73]. Several centres have produced world-leading outputs in the last decade with international collaborators.…”

Section: Priority 4: Provide Sufficient Evidence Of Therapeutic Oppor...mentioning

confidence: 99%

Adult brain tumour research in 2024: Status, challenges and recommendations

Purshouse,

Bulbeck,

Rooney

et al. 2024

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government pledging £20m of funding, to be paralleled with £25m from Cancer Research UK, specifically for neuro‐oncology research over the subsequent 5 years. Herein, we review if and how the adult brain tumour research landscape in the United Kingdom has changed over that time and what challenges and bottlenecks remain. We have identified seven universal brain tumour research priorities and three cross‐cutting themes, which span the research spectrum from bench to bedside and back again. We discuss the status, challenges and recommendations for each one, specific to the United Kingdom.

show abstract

Section: Priority 4: Provide Sufficient Evidence Of Therapeutic Oppor...mentioning

confidence: 99%

Adult brain tumour research in 2024: Status, challenges and recommendations

Purshouse,

Bulbeck,

Rooney

et al. 2024

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

show abstract

“…Exploiting and extending more clinical trial centers can be a solution plus donating more grants for the brain cancer research portfolio. [287][288][289][290][291][292] Thus, even though nanomedicine is a crucial milestone in brain cancer treatment but it requires a better understanding of other essential key elements for further reliable advancements.…”

Section: Concluding Remarks and Future Perspectivesmentioning

confidence: 99%

Nanocarriers Call the Last Shot in the Treatment of Brain Cancers

Mehrabian

Mashreghi

Dadpour

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Our brain is protected by physio-biological barriers. The blood–brain barrier (BBB) main mechanism of protection relates to the abundance of tight junctions (TJs) and efflux pumps. Although BBB is crucial for healthy brain protection against toxins, it also leads to failure in a devastating disease like brain cancer. Recently, nanocarriers have been shown to pass through the BBB and improve patients’ survival rates, thus becoming promising treatment strategies. Among nanocarriers, inorganic nanocarriers, solid lipid nanoparticles, liposomes, polymers, micelles, and dendrimers have reached clinical trials after delivering promising results in preclinical investigations. The size of these nanocarriers is between 10 and 1000 nm and is modified by surface attachment of proteins, peptides, antibodies, or surfactants. Multiple research groups have reported transcellular entrance as the main mechanism allowing for these nanocarriers to cross BBB. Transport proteins and transcellular lipophilic pathways exist in BBB for small and lipophilic molecules. Nanocarriers cannot enter via the paracellular route, which is limited to water-soluble agents due to the TJs and their small pore size. There are currently several nanocarriers in clinical trials for the treatment of brain cancer. This article reviews challenges as well as fitting attributes of nanocarriers for brain tumor treatment in preclinical and clinical studies.

show abstract

“…It has been shown that accelerating progress in cancer-related research through increasing research and development (R&D) expenditure has the potential to improve the health and quality of life of patients with CNS tumors (9,10). The clinical impact of a research output can be objectively measured using Alternative Metrics or "almetrics" like PlumX from Plum Analytics.…”

Section: Introductionmentioning

confidence: 99%

Primary Brain Tumor Research Productivity in Southeast Asia and Its Association With Socioeconomic Determinants and Burden of Disease

2020

View full text Add to dashboard Cite

BackgroundThere is an unmet need to assess research productivity from southeast Asia (SEA) regarding primary central nervous system (CNS) tumors. The country’s economy, landscape of neurology practice, and disease burden are hypothesized to correlate with scientific output. This study aimed to objectively measure the impact of published studies on primary brain tumors in SEA and to assess for correlation with socioeconomic determinants and burden of disease.MethodsWe systematically searched electronic databases for relevant articles from SEA on primary CNS tumor until July 31, 2020. Bibliometric indices were reported and subjected to correlational analysis with population size, gross domestic product (GDP) per capita, percentage (%) GDP for research and development (R&D), total number of neurologists, disease incidence, deaths, and disability-adjusted life years.ResultsA total of 549 articles were included, consisting primarily of case reports (n=187, 34.06%) and discussed gliomas (n=195, 35.52%). Singapore published the most number of the articles (n=246, 44.8%). Statistical analysis showed a positive correlation between %GDP for R&D and total publication. Additionally, negative relationships were noted between burden of disease and total neurologist with most bibliometric indices. However, GDP per capita was not correlated with measures for research productivity.ConclusionThe low impact of scientific output on primary CNS tumors in SEA does not address the growing epidemiology and burden of this disease. An increase in the GDP growth and financial and manpower investment to R&D may significantly improve research productivity in SEA.

show abstract

Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG

Abstract: General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms

Cited by 8 publications

References 13 publications

Adult brain tumour research in 2024: Status, challenges and recommendations

Adult brain tumour research in 2024: Status, challenges and recommendations

Nanocarriers Call the Last Shot in the Treatment of Brain Cancers

Primary Brain Tumor Research Productivity in Southeast Asia and Its Association With Socioeconomic Determinants and Burden of Disease

Contact Info

Product

Resources

About